Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kezar Life Sciences Inc.

4.61
-0.0900-1.91%
Volume:3.43K
Turnover:15.93K
Market Cap:33.68M
PE:-0.40
High:4.75
Open:4.70
Low:4.61
Close:4.70
Loading ...

Company Profile

Company Name:
Kezar Life Sciences Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
55
Office Location:
4000 Shoreline Court,Suite 300,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Directors

Name
Position
Jean Pierre Sommadossi
Chairman
John Fowler
Chief Executive Officer and Director
Christopher Kirk
President, Chief Scientific Officer and Director
Elizabeth Garner
Director
Franklin M. Berger
Director
Graham Cooper
Director
Jason Dinges
Director
Michael G. Kauffman
Director

Shareholders

Name
Position
John Fowler
Chief Executive Officer and Director
Marc L. Belsky
Chief Financial Officer and Secretary
Vassiliki Economides
Senior Vice President of Strategy and External Affairs
Christopher Kirk
President, Chief Scientific Officer and Director
Noreen Roth Henig
Chief Medical Officer